Ninerafaxstat is under clinical development by Imbria Pharmaceuticals and currently in Phase II for Hypertrophic Cardiomyopathy. According to GlobalData, Phase II drugs for Hypertrophic Cardiomyopathy have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ninerafaxstat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ninerafaxstat overview

ninerafaxstat is under development for the treatment of non-obstructive hypertrophic cardiomyopathy, myocardial ischemia, myocardial fibrosis, coronary artery disease (CAD), diabetic cardiomyopathy, stable angina and diastolic heart failure (HFpEF). It is administered through oral route as tablet. It was under development for systolic heart failure, refractory angina.

Imbria Pharmaceuticals overview

Imbria Pharmaceuticals is a biotechnology company that designed to translate the understanding of cellular metabolism into innovative medicines. The company is headquartered in United States.

For a complete picture of Ninerafaxstat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.